TECHNOLOGY
LICENSING
CANCER
Cancer is a disease that results from a series of oncogenic events that culminate in irreparable genetic damage to normal cells. These events ultimately give rise to the uncontrolled, invasive cellular growth termed malignant cancer. Together with collaborators, our Company has identified key target proteins that are involved both initially as well as in the later stages of growth of certain forms of human cancer. These target proteins remain functional when patients relapse after being treated with an initially effective drug regimen. Our findings suggest powerful new strategies for identifying new molecular entities that will interact with these target proteins and help to overcome the ability of advanced forms of cancer to resist effective drug treatment.
MEDICINE FOR THE WORLD'S WELL-BEING
